Kala Pharmaceuticals announced a public offering of 7.5 million shares of its common stock at $8.25 per share, according to a press release.
Underwriters of the offering will have the option to purchase an additional 1.125 million shares at the public offering price for a period of 30 days, the release said.
The offering, which is anticipated to close Oct. 5, is expected to result in gross proceeds of $61.9 million, according to the company.
Joint bookrunning managers for the offering are J.P. Morgan, BofA Merrill Lynch and Jefferies, with (Read more...)
Uncategorized